PEG-Exenatide Formulation for Extended Half-Life
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical formulations of peptide drugs like Exenatide for type 2 diabetes have short half-lives and require frequent administration, leading to compliance issues and potential side effects, while also facing challenges in stability and industrial production.
Innovation Solution
The development of a pharmaceutical composition of polyethylene glycol loxenatide, which includes the drug combined with a buffer and an isosmotic regulator, along with optional surfactants and stabilizers, to create a stable injection form that extends the drug's half-life and reduces administration frequency, using specific concentration ranges and pH control.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If Exenatide is used for type 2 diabetes treatment, then glycemic control is improved, but the half-life remains short (2-3 hours) requiring frequent administration
Solution Approach 1:
The patent applies PEGylation technology to combine Exenatide with polyethylene glycol chains, creating a composite molecular structure (PEG-Exenatide conjugate). This composite material approach extends the half-life from 2-3 hours to over 72 hours by reducing renal clearance and protecting against proteolytic degradation, thereby reducing administration frequency from twice daily to once weekly
Solution Approach 2:
The patent modifies the molecular parameters of Exenatide by changing its hydrodynamic radius, charge distribution, and solubility characteristics through PEG attachment. These parameter changes result in altered pharmacokinetic properties, specifically extending circulation half-life and reducing renal filtration rate, which directly addresses the short duration of action
2Reliability
If peptide drugs are administered frequently to maintain efficacy, then glycemic control is maintained, but patient compliance deteriorates
Solution Approach 1:
The patent transforms the administration regimen from frequent periodic injections (twice daily) to a single weekly injection. The PEG-Exenatide conjugate maintains stable plasma concentrations throughout the week, providing continuous glycemic control through a simplified periodic dosing schedule that significantly improves patient compliance
3Stability of the object's composition
If more stabilizers and additives are added to improve formulation stability, then shelf life is extended, but formulation complexity increases
Solution Approach 1:
The patent eliminates the need for multiple stabilizers, antioxidants, and preservatives that are typically required in peptide formulations by incorporating the stabilizing function directly into the PEG-Exenatide molecular structure. The PEG moiety provides inherent protection against aggregation and degradation, allowing for a simplified formulation with fewer excipients
Data Source
AI summary
Disclosed are a GLP-1-mimicking pharmaceutical composition for treating type 2 diabetes and a preparation method thereof, wherein the pharmaceutical composition contains polyethylene glycol loxenatide, a physiologically acceptable buffer with the pH of 3.0-7.0, and pharmaceutically acceptable excipients. The pharmaceutical composition has good drug stability.